Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5397_Библиотеки_им_академика_М_И_Перельмана
.pdf
15 Biotechnological Approaches inInfectious Diseases
https://t.me/med1917
scaffold facilitated the gradual release of silver, yet it did not decrease toxicity to
host cells (Mohiti-Asli etal. 2014). Continued research in this domain might be
very benecial.
309
15.3 Eliminating Anti-infective Drug Resistance
The development of resistance to pathogens is a major and increasing challenge in
the ght against IDs. Pathogens may acquire resistance by a number of mechanisms, including the production of drug-inactivating enzymes, an intracellular life
cycle, biolm formation, decreased metabolic activity, or the fact that they are obligate intracellular pathogens (Munita and Arias 2016). Ineffectiveness against intracellular infections may be caused by poor drug diffusion through the membrane of
the host cells and its active efux via drug transporters (Carryn etal. 2003). Since
pathogens and drug molecules are not colocalized inside host cells, effectiveness is
reduced, adding another layer of complication. Aminoglycosides, for instance, prefer to accumulate in the lysosomes, making them useless against cytosolic pathogens (Tulkens and Trouet 1978). Therefore, methods that boost drug accumulation
within cells and direct medications to specic subcellular sites may be more effective. By enclosing anti-infectives in NCs, it may be possible to improve their absorption by cells and to modify their intracellular disposition. Improvements in
gentamicin administration to cytoplasmic organisms like Listeria monocytogenes
and Salmonella typhimurium were tried by Lutwyche etal. (1998). Fusogenic liposomes, which are stable at neutral pH but dissolve in the acidic environment of
endolysosomes, were used to encapsulate gentamycin. The medication is released
into the cytoplasm as the endosomal membrane is destabilized by lipid fusion. The
scientists used two liposomal formulations, one having a uorescence resonance
energy transfer pair and the other without, to verify the acid-mediated disintegration
of the liposomes. This mixture’s low baseline uorescence was due to the closeness
of the uorescent molecules. However, when the solution was made acidic, the liposomes ruptured and the lipids mingled, which dequenched the uorescence.
Gentamicin loaded into pH-sensitive liposomes was three times as effective as the
free antibiotic in an invitro model of infection with recombinant S. typhimurium.
Although pH-insensitive liposomes were taken up by cells to a greater extent, their
activity lagged behind that of the pH-sensitive formulation. The authors uorescently labeled liposomes that were released and metabolized by cellular enzymes to
investigate the process. Only pH-sensitive liposomes produced the marker intracellularly in mouse macrophages, as shown by confocal imaging. Balomycin, an
endosome acidication inhibitor, suppressed marker release. The importance of
intracellular targeting was shown, and the molecular specics of the roles played by
each component of the formulation were presented in this work.
Clemens et al. (2012) developed mesoporous silicon NPs with isoniazid to
target intracellular M. tuberculosis. The NPs’ pores were sealed with β-cyclodextrin,
effectively preventing drug leakage under neutral pH conditions. However, as the

310
https://t.me/med1917
S. Banerjee et al.
pH becomes acidic, the plug dissolves, leading to the release of the medication.
Sémiramoth etal. (2012) chemically linked penicillin G to hydrophobic squalene
by a pH-sensitive ester bond. The cells quickly internalized NPs produced from
this combination and then released the drug inside the endolysosomes.
Consequently, there was enhanced efcacy compared to the unbound medication.
The process of analyzing and understanding the ways by which bacteria take up
NCs on their surface has been utilized to enhance the transport of substances
within cells. Invasin, a protein produced by Yersinia pseudotuberculosis, attaches
to integrins on the surface of host cells. This attachment leads to a rearrangement
of the host cell’s cytoskeleton and allows the bacteria to be taken up into membrane-bound structures. Labouta etal. (2015) conducted reverse engineering of
this process by linking liposomes to the C-terminal portion of invasin, known as
InvA497, on the surface. Confocal microscopy investigations conducted in Hep-2
cells demonstrated that InvA497-functionalized liposomes exhibited a signicant
increase in cell binding (>30-fold) compared to albumin-functionalized liposomes. Furthermore, this enhanced cell binding was eliminated in competition
trials. InvA497-functionalized gentamycin-loaded liposomes exhibited a 30%
decrease in bacterial load in a laboratory model of Y. pseudotuberculosis infec-
tion, but albumin-functionalized liposomes did not have any impact. This study
has shown that the addition of InvA497 to the surface of polymeric NPs has positive effects on both the absorption of the NPs by cells in a laboratory context and
their ability to kill microbes. This notion is incredibly creative and would benet
from in vivo examination. Moreover, if these systems are administered orally,
then it is crucial to comprehend the stability of the peptides in the enzyme-abundant gastrointestinal environment. Understanding the immune response to systemically delivered NCs functionalized with bacterial peptides is crucial for
determining their pharmacokinetics and tolerability.
Efcient intracellular transport is crucial for molecules like messenger RNA,
which have garnered signicant interest for their use in immunization. The
majority of nucleic acid and protein delivery systems that are based on polymers
are inuenced by the pioneering research conducted by Langer and Folkman
(1976). Their work demonstrated that macromolecules, including proteins,
could be enclosed within small carriers made of polymers. This was initially
considered improbable because of the usage of organic solvents in the synthesizing process and the perceived impermeability of polymers to macromolecules
(Ditlev et al. 2018). After successfully demonstrating the proof-of-concept
using polymers, researchers showed how RNA could be encapsulated in lipid
carriers and its usefulness in immunization. NCs play a crucial role in facilitating the transportation of mRNA through the cellular membranes, allowing for
endolysosomal escaping and the release of nucleic acid in the cytoplasm. For
instance, self-replicating mRNA that codes for an antigen protein was combined
with a polymer based on cationic dendrimers. Animals that received mRNA NPs
exhibited immunological responses characterized by the production of antibodies and the activation of CD8+ T-cells. Furthermore, these animals were fully
shielded against fatal infections caused by Toxoplasma gondii, H1N1 inuenza,

15 Biotechnological Approaches inInfectious Diseases
https://t.me/med1917
and Ebola virus. Clinical trials have examined mRNA vaccines using lipid NCs,
with participation from industries like Moderna, BioNTech, Acuitas
Therapeutics, Pzer, GlaxoSmithKline, Translate Bio, Sano, and others.
Preliminary ndings demonstrate that lipid-NP-formulated mRNA vaccines targeting SARS-CoV-2 and H7N9, H10N8 inuenza viruses are well tolerated and
elicit a strong humoral response (Jackson et al. 2020; Feldman et al. 2019).
More precisely, mRNA-based vaccines have shown a level of effectiveness over
90% in combating SARS-CoV-2. The long-term viability of mRNA-based vaccinations over extended storage and transportation may pose signicant challenges to their usage in resource-constrained environments. NPs containing
peptide-based antigens have been produced for the purpose of vaccinating
against SARS-CoV-2 (Tian etal. 2021). Nanoencapsulation has been utilized to
target antibiotics to intracellular vesicles since bacteria and NCs have the ability
to aggregate in these vesicles. Couvreur etal. demonstrated the co-localization
of poly(cyanoacrylate) NPs with S. typhimurium in phagosomes of macrophages
utilizing confocal and transmission electron microscopy. This led to an improved
targeting of ampicillin inside the cells (Pinto-Alphandary etal. 1994). Toti etal.
( 2011) conducted a separate investigation and discovered that PLGA NPs,
which contained a uorescent dye, gathered together with chlamydial inclusion
bodies in infected human lung epithelial cells (Toti etal. 2011). Experiments
conducted in a controlled laboratory environment showed that antibiotics
(rifampicin and azithromycin) were shown to be efcacious when administered
promptly after infection, but their effectiveness diminished when administered
after 24 or 48h. Nevertheless, the activities of the NPs were partially recovered
even when administered 24 and 48h after infection. NPs possess the ability to
hinder, interrupt, or disseminate bacteria found in biolm infections (Han etal.
2017). The extracellular polymeric matrix in the biolm acts as a diffusion bar-
rier, providing protection to bacteria against elevated antibiotic concentrations,
which often results in the development of persistent infections. Teirlinck etal.
(2018) demonstrated that when gold NPs were exposed to laser irradiation,
nanobubbles were developed, which caused the diffusion barrier to be disrupted.
The local disturbance of the biolms resulted in heightened permeability,
thereby rendering them more susceptible to the antibiotic tobramycin.
311
15.4 Clinical andPreclinical Nanotechnology Advancements
This section focuses on the modern nanotechnologies used in the treatment of
important infectious diseases such as tuberculosis, malaria, and HIV infection. The
information indicates that nanotechnology has been extensively researched in clinical contexts and with large animals for the purpose of treating and preventing HIV
infection. Conversely, nanotechnology was explored with less enthusiasm for TB
and malaria. These IDs have mostly been tested in preclinical experiments involving
animals. The data are listed in Table15.1.

312
https://t.me/med1917
S. Banerjee et al.
Reduced dose frequency
Reactions at injection
sites are rather frequent,
refrigeration required
(NCT04542070,
NCT02938520,
Cabotegravir
Reduced dose
frequency
Daily dosing is required Omits potentially harmful excipients
caregiver
NCT02951052)
(rodent model)
Optimal drug transport to the lungs
Improved bio-availability, target alveolar
Macrophages, avoid rst-pass metabolism
Reduced dose frequency, improved
bio-availability
Superior bio-availability compared to oral
forms, reduced dose frequency
Improved bio-availability
training
BCG vaccine Will need patient
Frequent dosing is
required, devoid of
pyrazinamide–ethambutol–
streptomycin
pyrazinamide
ethambutol
caregiver
Target contaminated erythrocytes, enhance
the lipophilic drug’s solubility
microemulsions with the
use of high surfactant
concentrations
Needs the help of a
caregiver
Chloroquine derivative (novel
aminoalcohol derivative)
Disease
name Formulation Drug name Testing phase Limitation Advancement
Table 15.1 Nanotechnology for the treatment of IDs in preclinical and clinical facilities (https://clinicaltrials.gov/)
HIV Injectable NPs Rilpivirine Phase III
Oral NPs Lopinavir–efavirenz Preclinical
Injectable NPs Dolutegravir Needs the help of a
Injectable lipid NPs Lopinavir–ritonavir–tenofovir Target macrophages
TB Aerosolized
micro-NPs
Oral polymer NPs Rifampicin–isoniazid–
Oral lipid NPs Rifampicin–isoniazid–
Microemulsion Artemether–tafenoquine Stabilizing
Malaria Injectable NPs Artemether–lumefantrine Needs the help of a
Injectable
immune- liposomes

15 Biotechnological Approaches inInfectious Diseases
https://t.me/med1917
313
15.5 Limitations andFuture Prospects
The aforementioned examples demonstrate several potential therapeutic
approaches in the development of nanomedicines for the treatment and prevention
of infectious diseases. Nevertheless, in order to have the greatest inuence, nanotechnology approaches must surmount several economic, commercial, and regulatory obstacles. Initially, the primary challenge is in minimizing the expenses
associated with the development of novel medications and nanotechnology-driven
systems. The discovery of novel pharmaceuticals for global health solutions is a
costly endeavor.
Repurposing established medications inside NCs might potentially attain comparable objectives of heightened effectiveness and safety at a much-reduced cost.
Nevertheless, a single nano-system that has been ofcially sanctioned (namely, an
amphotericin B liposomal formulation) is not economically viable in poor nations
(Sundar and Chakravarty 2010). The inclusion of excipients, such as lyoprotectants,
in nanosystems may lead to an increase in the overall cost of various therapies.
Furthermore, the production and preservation circumstances of some NPs might not
be suitable for low-resource countries (Mitchell and Carlson 2018). Researchers
must ensure the repeatability and scalability of these nanosystems while also taking
into account their environmental impact.
Nanomedicines are expected to be complex structures consisting of numerous components arranged in certain spatial congurations. Minor alterations in
procedure or structure may have a negative impact on the exact construction of
nanomedicines (Desai 2012; Ioannidis etal. 2018). Furthermore, the presence
of regional and national variations within and across regulatory bodies poses a
signicant problem, particularly when conducting multinational clinical trials.
Ultimately, it is crucial to consider the level of acceptance among patients about
these nanosystems. Legal action was taken against the FDA in 2006 by the
International Centre for Technology Assessment and other consumer groups
who claimed the agency was too slow to regulate products using nanomaterials.
In light of recent developments, the FDA formed the Nano Task Force. An interconnected group of stakeholders must collaborate for the effective implementation of nanomedicines into clinical practice. This includes individuals from the
academic eld, investors from many industries, government representatives, and
contract research and production organizations. Nanotechnology is a multidisciplinary area that necessitates the use of intellectual property and commercialization methods in order to expand and develop. However, the rapid application
of nanotechnologies from the laboratory to the general population and the signicant inuence these systems have made on the SARS-CoV-2 epidemic provide considerable potential. This example implies that such achievements may
be feasible in addressing other contagious illnesses as well.

314
https://t.me/med1917
S. Banerjee et al.
15.6 Conclusions
Identication numbers have a signicant inuence on the occurrence of illness and
death worldwide, with a particularly severe effect on nations with low SDI.Enhancing
the accessibility and effectiveness of medications may enhance the patients’ wellbeing and alleviate the impact of diseases. This chapter focuses on the use of
nanotechnology- based methods to enhance oral medication delivery, reduce the frequency of drug administration, and target drugs to specic infection areas, hence
enhancing the effectiveness of therapy. Ultimately, it examined instances of nanotechnologies now undergoing clinical trials for HIV therapy and in the preclinical
stage of development for TB and malaria treatment. Nanotechnologies that are both
innovative and cost-effective, and specically designed to address the issues faced
by low-SDI nations, are expected to have the most positive impact on patients.
References
Alvarez CA, Wiederhold NP, McConville JT, Peters JI, Najvar LK, Graybill JR et al (2007)
Aerosolized nanostructured itraconazole as prophylaxis against invasive pulmonary aspergil-
losis. J Infect 55(1):68–74
Anselmo AC, Mitragotri S (2016) Nanoparticles in the clinic. Bioeng Transl Med 1(1):10–29
Arias JL, Unciti-Broceta JD, Maceira J, Del Castillo T, Hernández-Quero J, Magez S etal (2015)
Nanobody conjugated PLGA nanoparticles for active targeting of African Trypanosomiasis. J
Control Release 197:190–198
Azad AK, Rajaram MV, Schlesinger LS (2014) Exploitation of the macrophage mannose receptor
(CD206) in infectious disease diagnostics and therapeutics. J Cytol Mol Biol 1(1):1000003
Bakker-Woudenberg IA, Lokerse AF, ten Kate MT, Storm G (1992) Enhanced localization of lipo-
somes with prolonged blood circulation time in infected lung tissue. Biochim Biophys Acta
Mol Basis Dis 1138(4):318–326
Bakker-Woudenberg I, Lokerse AF, Mt K, Mouton J, Woodle M, Storm G (1993) Liposomes with
prolonged blood circulation and selective localization in Klebsiella pneumoniae-infected lung
tissue. J Infect Dis 168(1):164–171
Carryn S, Chanteux H, Seral C, Mingeot-Leclercq M-P, Van Bambeke F, Tulkens PM (2003)
Intracellular pharmacodynamics of antibiotics. Infect Dis Clin 17(3):615–634
Clemens DL, Lee B-Y, Xue M, Thomas CR, Meng H, Ferris D etal (2012) Targeted intracel-
lular delivery of antituberculosis drugs to Mycobacterium tuberculosis-infected macro-
phages via functionalized mesoporous silica nanoparticles. Antimicrob Agents Chemother
56(5):2535–2545
Cu Y, Booth CJ, Saltzman WM (2011) In vivo distribution of surface-modied PLGA nanopar-
ticles following intravaginal delivery. J Control Release 156(2):258–264
Cunha-Reis C, Machado A, Barreiros L, Araújo F, Nunes R, Seabra V etal (2016) Nanoparticles-
in- lm for the combined vaginal delivery of anti-HIV microbicide drugs. J Control Release
243:43–53
das Neves J, Nunes R, Machado A, Sarmento B (2015) Polymer-based nanocarriers for vaginal
drug delivery. Adv Drug Deliv Rev 92:53–70
Desai N (2012) Challenges in development of nanoparticle-based therapeutics. AAPS J
14(2):282–295

15 Biotechnological Approaches inInfectious Diseases
https://t.me/med1917
Ditlev JA, Case LB, Rosen MK (2018) Who’s in and who’s out—compositional control of biomo-
lecular condensates. J Mol Biol 430(23):4666–4684
Duong HT, Jung K, Kutty SK, Agustina S, Adnan NNM, Basuki JS etal (2014) Nanoparticle (star
polymer) delivery of nitric oxide effectively negates Pseudomonas aeruginosa biolm forma-
tion. Biomacromolecules 15(7):2583–2589
Ensign LM, Tang BC, Wang Y-Y, Tse TA, Hoen T, Cone R et al (2012) Mucus-penetrating
nanoparticles for vaginal drug delivery protect against herpes simplex virus. Sci Transl Med
4(138):138ra79-ra 79
Feldman RA, Fuhr R, Smolenov I, Ribeiro AM, Panther L, Watson M etal (2019) mRNA vaccines
against H10N8 and H7N9 inuenza viruses of pandemic potential are immunogenic and well
tolerated in healthy adults in phase 1 randomized clinical trials. Vaccine 37(25):3326–3334
Fielding RM, Lewis RO, Moon-McDermott L (1998) Altered tissue distribution and elimination
of amikacin encapsulated in unilamellar, low-clearance liposomes (MiKasome®). Pharm Res
15:1775–1781
Han C, Romero N, Fischer S, Dookran J, Berger A, Doiron AL (2017) Recent developments in the
use of nanoparticles for treatment of biolms. Nanotechnol Rev 6(5):383–404
Huh AJ, Kwon YJ (2011) “Nanoantibiotics”: a new paradigm for treating infectious diseases using
nanomaterials in the antibiotics resistant era. J Control Release 156(2):128–145
Hussain S, Joo J, Kang J, Kim B, Braun GB, She Z-G etal (2018) Antibiotic-loaded nanoparticles
targeted to the site of infection enhance antibacterial efcacy. Nature Bio Eng 2(2):95–103
Huth M, Ricci A, Cheng A (2011) Mechanisms of aminoglycoside ototoxicity and targets of hair
cell protection. Int J Otol 2011:937861
Ioannidis JP, Kim BY, Trounson A (2018) How to design preclinical studies in nanomedicine and
cell therapy to maximize the prospects of clinical translation. Nat Biol Eng 2(11):797–809
Irvine DJ, Hanson MC, Rakhra K, Tokatlian T (2015) Synthetic nanoparticles for vaccines and
immunotherapy. Chem Rev 115(19):11109–11146
Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN etal (2020) An
mRNA vaccine against SARS-CoV-2—preliminary report. N Engl J Med 383(20):1920–1931
James GA, Swogger E, Wolcott R, Ed P, Secor P, Sestrich J etal (2008) Biolms in chronic
wounds. Wound Repair Regen 16(1):37–44
Jawahar N, Meyyanathan S (2012) Polymeric nanoparticles for drug delivery and targeting: a
comprehensive review. Int J Health Allied Sci 1(4):217
Kaminishi H, Tanaka M, Cho T, Maeda H, Hagihara Y (1990) Activation of the plasma kallikrein-
kinin system by Candida albicans proteinase. Infect Immun 58(7):2139–2143
Kim M-H, Yamayoshi I, Mathew S, Lin H, Nayfach J, Simon SI (2013) Magnetic nanoparti-
cle targeted hyperthermia of cutaneous Staphylococcus aureus infection. Ann Biomed Eng
41:598–609
Kinch MS, Patridge E, Plummer M, Hoyer D (2014) An analysis of FDA-approved drugs for infec-
tious disease: antibacterial agents. Drug Discov Today 19(9):1283–1287
Kirtane AR, Langer R, Traverso G (2016) Past, present, and future drug delivery systems for anti-
retrovirals. J Pharm Sci 105(12):3471–3482
Labouta HI, Menina S, Kochut A, Gordon S, Geyer R, Dersch P etal (2015) Bacteriomimetic
invasin-functionalized nanocarriers for intracellular delivery. J Control Release 220:414–424
Lai SK, O'Hanlon DE, Harrold S, Man ST, Wang Y-Y, Cone R etal (2007) Rapid transport of large
polymeric nanoparticles in fresh undiluted human mucus. Proc Natl Acad Sci 104(5):1482–1487
Landovitz RJ, Kofron R, McCauley M (2016) The promise and pitfalls of long acting injectable
agents for HIV prevention. Curr Opin HIV AIDS 11(1):122
Langer R, Folkman J (1976) Polymers for the sustained release of proteins and other macromol-
ecules. Nature 263(5580):797–800
Laverman P, Boerman OC, Oyen WJ, Dams ETM, Storm G, Corstens FH (1999) Liposomes for
scintigraphic detection of infection and inammation. Adv Drug Deliv Rev 37(1–3):225–235
Leal J, Smyth HD, Ghosh D (2017) Physicochemical properties of mucus and their impact on
transmucosal drug delivery. Int J Pharm 532(1):555–572
315

316
https://t.me/med1917
Löbenberg R, Araujo L, von Briesen H, Rodgers E, Kreuter J (1998) Body distribution of azidothy-
midine bound to hexyl-cyanoacrylate nanoparticles after IV injection to rats. J Control Release
50(1–3):21–30
Lutwyche P, Cordeiro C, Wiseman DJ, St-Louis M, Uh M, Hope MJ etal (1998) Intracellular
delivery and antibacterial activity of gentamicin encapsulated in pH-sensitive liposomes.
Antimicrob Agents Chemother 42(10):2511–2520
Makadia HK, Siegel SJ (2011) Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled
drug delivery carrier. Polymers 3(3):1377–1397
Manzari MT, Shamay Y, Kiguchi H, Rosen N, Scaltriti M, Heller DA (2021) Targeted drug deliv-
ery strategies for precision medicines. Nat Rev Mater 6(4):351–370
Martinez LR, Han G, Chacko M, Mihu MR, Jacobson M, Gialanella P etal (2009) Antimicrobial
and healing efcacy of sustained release nitric oxide nanoparticles against Staphylococcus
aureus skin infection. J Invest Dermatol 129(10):2463–2469
McMillan J, Szlachetka A, Slack L, Sillman B, Lamberty B, Morsey B etal (2018) Pharmacokinetics
of a long-acting nanoformulated dolutegravir prodrug in rhesus macaques. Antimicrob Agents
Chemother 62(1):10.1128/aac. 01316-17
Mitchell SL, Carlson EE (2018) Tiny things with enormous impact: nanotechnology in the ght
against infectious disease. ACS infect dis 4(10):1432–1435
Mohiti-Asli M, Pourdeyhimi B, Loboa EG (2014) Skin tissue engineering for the infected wound
site: biodegradable PLA nanobers and a novel approach for silver ion release evaluated in a
3D coculture system of keratinocytes and Staphylococcus aureus. Tissue Eng Part C Methods
20(10):790–797
Molla A, Yamamoto T, Akaike T, Miyoshi S, Maeda H (1989) Activation of Hageman fac-
tor and prekallikrein and generation of kinin by various microbial proteinases. J Biol Chem
264(18):10589–10594
Munita JM, Arias CA.Mechanisms of antibiotic resistance. Virulence mechanisms of bacterial
pathogens 2016: 4 (2) 481–511
Nafee N, Husari A, Maurer CK, Lu C, de Rossi C, Steinbach A etal (2014) Antibiotic-free nano-
therapeutics: ultra-small, mucus-penetrating solid lipid nanoparticles enhance the pulmonary
delivery and anti-virulence efcacy of novel quorum sensing inhibitors. J Control Release
192:131–140
Palliser D, Chowdhury D, Wang Q-Y, Lee SJ, Bronson RT, Knipe DM etal (2006) An siRNA-
based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature
439(7072):89–94
Pardi N, Hogan MJ, Porter FW, Weissman D (2018) mRNA vaccines—a new era in vaccinology.
Nat Rev Drug Discov 17(4):261–279
Pheage T (2017) Dying from lack of medicines. Afr Renew 30(3):24–25
Pinto-Alphandary H, Balland O, Laurent M, Andremont A, Puisieux F, Couvreur P (1994)
Intracellular visualization of ampicillin-loaded nanoparticles in peritoneal macrophages
infected invitro with Salmonella typhimurium. Pharm Res 11:38–46
Roth GA, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N etal (2018) Global, regional,
and national age-sex-specic mortality for 282 causes of death in 195 countries and territo-
ries, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet
392(10159):1736–1788
Roy I, Vij N (2010) Nanodelivery in airway diseases: challenges and therapeutic applications.
Nanomedicine 6(2):237–244
Sabaté E (2003) Adherence to long-term therapies: evidence for action. World Health Organization
Sarathy JP, Zuccotto F, Hsinpin H, Sandberg L, Via LE, Marriner GA etal (2016) Prediction of
drug penetration in tuberculosis lesions. ACS Infect Dis 2(8):552–563
Schiffelers R, Storm G, Bakker-Woudenberg I (2001) Liposome-encapsulated aminoglycosides in
pre-clinical and clinical studies. J Antimicrob Chemother 48(3):333–344
S. Banerjee et al.

15 Biotechnological Approaches inInfectious Diseases
https://t.me/med1917
Semiramoth N, Meo CD, Zouhiri F, Said-Hassane F, Valetti S, Gorges R etal (2012) Self-assembled
squalenoylated penicillin bioconjugates: an original approach for the treatment of intracellular
infections. ACS Nano 6(5):3820–3831
Sen CK, Gordillo GM, Roy S, Kirsner R, Lambert L, Hunt TK etal (2009) Human skin wounds:
a major and snowballing threat to public health and the economy. Wound Repair Regen
17(6):763–771
Siegel RA, Kirtane AR, Panyam J (2016) Assessing the benets of drug delivery by nanocarriers: a
partico/pharmacokinetic framework. IEEE Trans Biomed Eng 64(9):2176–2185
Steinbach JM, Weller CE, Booth CJ, Saltzman WM (2012) Polymer nanoparticles encapsulating
siRNA for treatment of HSV-2 genital infection. J Control Release 162(1):102–110
Suk JS, Boylan NJ, Trehan K, Tang BC, Schneider CS, Lin J-MG etal (2011) N-acetylcysteine
enhances cystic brosis sputum penetration and airway gene transfer by highly compacted
DNA nanoparticles. Mol Ther 19(11):1981–1989
Sundar S, Chakravarty J (2010) Liposomal amphotericin B and leishmaniasis: dose and response.
J Global Infect Dis 2(2):159
Tedijanto C, Olesen SW, Grad YH, Lipsitch M (2018) Estimating the proportion of bystander
selection for antibiotic resistance among potentially pathogenic bacterial ora. Proc Natl Acad
Sci 115(51):E11988–E11E95
Teirlinck E, Xiong R, Brans T, Forier K, Fraire J, Van Acker H etal (2018) Laser-induced vapour
nanobubbles improve drug diffusion and efciency in bacterial biolms. Nat Commun
9(1):4518
Tian J-H, Patel N, Haupt R, Zhou H, Weston S, Hammond H etal (2021) SARS-CoV-2 spike
glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in
mice. Nat Commun 12(1):372
Toti US, Guru BR, Hali M, McPharlin CM, Wykes SM, Panyam J etal (2011) Targeted delivery
of antibiotics to intracellular chlamydial infections using PLGA nanoparticles. Biomaterials
32(27):6606–6613
Trezza C, Ford SL, Spreen W, Pan R, Piscitelli S (2015) Formulation and pharmacology of long-
acting cabotegravir. Curr Opin HIV AIDS 10(4):239
Tulkens P, Trouet A (1978) The uptake and intracellular accumulation of aminoglycoside antibiot-
ics in lysosomes of cultured rat broblasts. Biochem Pharmacol 27(4):415–424
Vaughn JM, McConville JT, Burgess D, Peters JI, Johnston KP, Talbert RL etal (2006) Single dose
and multiple dose studies of itraconazole nanoparticles. Eur J Pharm Biopharm 63(2):95–102
Williams PE, Crauwels HM, Basstanie ED (2015) Formulation and pharmacology of long-acting
rilpivirine. Curr Opin HIV AIDS 10(4):233–238
Wistrand-Yuen E, Knopp M, Hjort K, Koskiniemi S, Berg OG, Andersson DI (2018) Evolution of
high-level resistance during low-level antibiotic exposure. Nat Commun 9(1):1599
Wong JP, Yang H, Blasetti KL, Schnell G, Conley J, Schoeld LN (2003) Liposome delivery
of ciprooxacin against intracellular Francisella tularensis infection. J Control Release
92(3):265–273
World Health Organization, and Stop TB Initiative. (2010) Treatment of tuberculosis: guidelines.
World Health Organization, Geneva
Xiong MH, Li YJ, Bao Y, Yang XZ, Hu B, Wang J (2012a) Bacteria-responsive multifunctional
nanogel for targeted antibiotic delivery. Adv Mater 24(46):6175–6180
Xiong M-H, Bao Y, Yang X-Z, Wang Y-C, Sun B, Wang J (2012b) Lipase-sensitive polymeric
triple-layered nanogel for “on-demand” drug delivery. J Am Chem Soc 134(9):4355–4362
Zhang CY, Gao J, Wang Z (2018) Bioresponsive nanoparticles targeted to infectious microenviron-
ments for sepsis management. Adv Mater 30(43):1803618
317

Chapter 16
https://t.me/med1917
Forensic Drug Chemistry: Unravelling
Evidence Through Scientic Analysis
AbuMdAshifIkbal, RabinDebnath, SabuThomas,
DebprasadChattopadhyay, andParthaPalit
Abstract Forensic drug chemistry plays a pivotal role in modern criminal investi-
gations by utilising scientic methods to identify, analyse, and interpret illicit substances at crime scenes. This interdisciplinary eld merges principles from
chemistry, pharmacology, and law enforcement to provide accurate and reliable
evidence that assists in establishing connections between individuals, substances,
and criminal activities. The primary objective of forensic drug chemistry is to determine the presence and composition of controlled substances, such as illegal drugs
and prescription medications, in various samples recovered from crime scenes. The
constant emergence of new designer drugs, synthetic compounds, and modied
substances necessitates continuous research and method development to ensure
accurate identication and classication. The results obtained from forensic analyses can determine the course of an investigation, inuence legal decisions, and
impact the lives of both victims and suspects. Moreover, forensic drug chemistry
extends beyond identifying substances; it aids in uncovering patterns of drug trafcking, manufacturing, and distribution. In conclusion, forensic drug chemistry
stands as an indispensable component of modern forensic science. Through its scientic rigour and multidisciplinary approach, this area provides crucial information
A. M. A. Ikbal · P. Palit (*)
Department of Pharmaceutical Sciences, Drug Discovery Research Laboratory, Assam
University (A Central University), Silchar, India
R. Debnath
ISF College of Pharmacy, Moga, Punjab, India
S. Thomas
School of Chemical Sciences, Mahatma Gandhi University, Kottayam, India
e-mail: sabu.thomas@mgu.ac.in
D. Chattopadhyay
Natural product, ICMR-National Institute of Traditional Medicine, Nehru Nagar, Belagavi,
Karnataka, India
ICMR-National Institute of Traditional Medicine, Belagavi, India
School of Life Sciences, Swami Vivekananda University Barrackpore, Kolkata, India
Ltd. 2024
S. Bose et al. (eds.), Concepts in Pharmaceutical Biotechnology and Drug
Development, Interdisciplinary Biotechnological Advances,
https://doi.org/10.1007/978-981-97-1148-2_16
319© The Author(s), under exclusive license to Springer Nature Singapore Pte
Соседние файлы в папке Библиотека им академика М.И. Перельмана
